⚠️ Pediatric Adolescent GLP-1 Therapy Safety Simulator

Screening Adolescents for GLP-1 Therapy Candidacy

Placeholder: age, pediatric BMI percentile, and comorbidity criteria reviewed.

• 12 yrs: Minimum age (Placeholder eligibility floor)
• ≥95th pct: BMI threshold (Placeholder age/sex-adjusted)
• Required: Comorbidity screen (Placeholder pre-therapy workup)
• Pediatric endo: Specialist referral (Placeholder care team)

Eligibility criteria overview

Placeholder: age and BMI percentile define candidacy, not adult BMI cutoffs.

Baseline health assessment

Placeholder: labs, growth history, and pubertal stage recorded before start.

Placeholder highlight: pediatric criteria differ meaningfully from adult thresholds.

Age-Adjusted Titration Distinct From Adult Protocols

Placeholder: dosing scales to body weight with a slower titration curve.

• Slower: Titration pace (Placeholder vs. adult schedule)
• mg/kg: Dosing basis (Placeholder weight-adjusted)
• Low: Starting dose (Placeholder conservative start)
• 4 weeks: Titration interval (Placeholder step-up cadence)

Weight-based dose calculation

Placeholder: dose scaled per kilogram, reassessed as weight changes.

Titration safety checkpoints

Placeholder: GI tolerability reviewed before each dose increase step.

Placeholder highlight: slower titration reduces adverse event frequency in teens.

Tracking Height Velocity and Pubertal Staging During Therapy

Placeholder: growth curves monitored alongside weight to catch deviations early.

• Every visit: Height check (Placeholder monitoring cadence)
• Tracked: Tanner staging (Placeholder pubertal assessment)
• CDC/WHO: Growth chart (Placeholder percentile reference)
• Velocity drop: Alert trigger (Placeholder safety flag)

Height velocity tracking

Placeholder: growth trajectory plotted against normative percentile bands.

Pubertal stage correlation

Placeholder: Tanner stage checked to contextualize expected growth pace.

Placeholder highlight: sustained growth deceleration prompts dose review.

Body Image, Family Support, and Peer Environment in Teens

Placeholder: adolescent-specific psychosocial factors shape therapy outcomes.

• Included: Body image screen (Placeholder assessment tool)
• Recommended: Family sessions (Placeholder involvement plan)
• Reviewed: School environment (Placeholder peer context)
• 0–100: Support score range (Placeholder composite metric)

Family-centered counseling

Placeholder: caregivers included in goal-setting and follow-up visits.

Peer and school context

Placeholder: school stigma and peer dynamics factored into care plan.

Placeholder highlight: higher family support correlates with better adherence.

Safety Profile Comparable to Adults, With Closer Pediatric Oversight

Placeholder: trial data shows adult-similar safety with added monitoring needs.

• Similar: Adverse event rate (Placeholder vs. adult trials)
• Closer: Growth monitoring (Placeholder pediatric requirement)
• Family-centered: Care model (Placeholder follow-up approach)
• Limited: Long-term data (Placeholder ongoing research need)

Trial safety summary

Placeholder: GI effects most common, consistent with adult safety data.

Long-term follow-up needs

Placeholder: growth, puberty, and psychosocial status reassessed periodically.

Placeholder highlight: family-centered follow-up remains central to pediatric safety.